标题
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-02
DOI
10.1186/s13045-020-00958-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
- (2020) Talia Golan et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
- (2020) Eric S Christenson et al. LANCET ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
- (2020) Takahiko Nishigaki et al. BRITISH JOURNAL OF CANCER
- Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
- (2020) Samarth Hegde et al. CANCER CELL
- Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
- (2020) Erik S Knudsen et al. GUT
- T cells expressing a chimeric‐PD1‐Dap10‐CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer
- (2020) Geoffrey Parriott et al. IMMUNOLOGY
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting KRAS G12C ‐mutant cancer with a mutation‐specific inhibitor
- (2020) James G. Christensen et al. JOURNAL OF INTERNAL MEDICINE
- Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
- (2020) Daniel Baumann et al. Nature Communications
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gain Fat—Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis
- (2019) Dana Ishay-Ronen et al. CANCER CELL
- KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer
- (2019) He Cheng et al. CANCER LETTERS
- Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
- (2019) Aesha I. Ali et al. Frontiers in Oncology
- CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
- (2019) Letizia Porcelli et al. Cancers
- Molecular subtypes of pancreatic cancer
- (2019) Eric A. Collisson et al. Nature Reviews Gastroenterology & Hepatology
- Anti-CD19 CAR T cell therapy for lymphoma — off to the races!
- (2019) David G. Maloney Nature Reviews Clinical Oncology
- Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance
- (2019) Toshiya Abe et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
- (2019) Davide Melisi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine
- (2019) Stephanie Lheureux et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma
- (2019) Martin R Jones et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
- (2019) Hengyu Lu et al. MOLECULAR CANCER THERAPEUTICS
- Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
- (2019) Stefan Mereiter et al. CANCER CELL
- Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
- (2019) Matteo Ligorio et al. CELL
- COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms
- (2019) Antje Lindemann et al. CLINICAL CANCER RESEARCH
- Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial‐mesenchymal transition in Panc‐1 and MiaPaCa‐2 pancreatic cancer cells
- (2019) Ozge Rencuzogulları et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Predicting Tumor Response to PD-1 Blockade
- (2019) Li Ding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
- (2019) Dannielle D. Engle et al. SCIENCE
- Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12
- (2019) Xiaowei Chi et al. Cancer Medicine
- Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
- (2019) Ivelina Gueorguieva et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
- (2019) Teena Dhir et al. MOLECULAR CANCER RESEARCH
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer
- (2019) Chen Liang et al. GUT
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
- (2019) Christopher Nevala-Plagemann et al. Nature Reviews Clinical Oncology
- CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
- (2019) Linchun Jin et al. Nature Communications
- Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
- (2019) Rita Sulahian et al. Cell Reports
- Natural killer cells; diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis
- (2019) Anahid Jewett et al. Molecular Therapy-Oncolytics
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
- (2018) Jaclyn Andricovich et al. CANCER CELL
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Immunotherapy for pancreatic cancer: A long and hopeful journey
- (2018) Jian-wei Xu et al. CANCER LETTERS
- EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
- (2018) Nicole M. Aiello et al. DEVELOPMENTAL CELL
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
- (2018) Renato M. Lupinacci et al. GASTROENTEROLOGY
- A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion
- (2018) Brendan Horton et al. IMMUNITY
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- New therapeutic strategies to treat human cancers expressing mutant p53 proteins
- (2018) Giovanni Blandino et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
- (2018) Reham Abdel-Wahab et al. Journal of Hematology & Oncology
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy
- (2018) Lu Wang et al. NATURE MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
- (2018) Frederick H. Wilson et al. Cancer Discovery
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- (2018) Alexander Drilon et al. Cancer Discovery
- ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
- (2018) Inna Smalley et al. Cancer Discovery
- NRG1 Fusions in KRAS Wild-type Pancreatic Cancer
- (2018) Christoph Heining et al. Cancer Discovery
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
- (2018) Yao Wang et al. OncoImmunology
- Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
- (2018) Zhi Rong Qian et al. JAMA Oncology
- Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy
- (2018) Wei Wang et al. CANCER RESEARCH
- Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
- (2018) Deepak Raj et al. GUT
- Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
- (2018) Erhao Zhang et al. Journal of Hematology & Oncology
- From somatic mutation to early detection: Insights from molecular characterization of pancreatic cancer precursor lesions
- (2018) Catherine G. Fischer et al. JOURNAL OF PATHOLOGY
- Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
- (2018) Hongmei Jiang et al. MOLECULAR CANCER THERAPEUTICS
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation
- (2018) Chong Du et al. ACS Nano
- Gastroenteropancreatic Neuroendocrine Tumors
- (2018) Mauro Cives et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- (2018) Vincent Bernard et al. CLINICAL CANCER RESEARCH
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors
- (2018) Pedro Torres-Ayuso et al. Cancer Discovery
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia
- (2017) Aatur D Singhi et al. GUT
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
- (2017) Gary Middleton et al. LANCET ONCOLOGY
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
- (2017) Sushrut Kamerkar et al. NATURE
- Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease
- (2017) Peter Sidaway Nature Reviews Clinical Oncology
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
- (2017) Khaldoun Almhanna et al. PHARMACOLOGY & THERAPEUTICS
- Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet
- (2017) P.E. Bunney et al. PHYSIOLOGY & BEHAVIOR
- Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
- (2017) Shomyseh Sanjabi et al. Cold Spring Harbor Perspectives in Biology
- FDA Approves Second CAR T-cell Therapy
- (2017) Cancer Discovery
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
- (2016) J. F. Liu et al. ANNALS OF ONCOLOGY
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Recent advances in cancer drug discovery targeting RAS
- (2016) Candice Y. Wilson et al. DRUG DISCOVERY TODAY
- Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
- (2016) Erik S. Knudsen et al. GASTROENTEROLOGY
- Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms
- (2016) Jun Yu et al. GUT
- Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer
- (2016) Ada G. Blidner et al. IMMUNITY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
- (2016) Hanane Laklai et al. NATURE MEDICINE
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Adding Value by Talking More
- (2016) Robert S. Kaplan et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib
- (2016) Mark A. Dickson et al. JAMA Oncology
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
- (2015) B. H. O'Neil et al. ANNALS OF ONCOLOGY
- RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma
- (2015) Martin C. Whittle et al. CELL
- Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
- (2015) H. J. Jacobsen et al. CLINICAL CANCER RESEARCH
- APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
- (2015) David S H Liu et al. GUT
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome analysis of pancreatic cancer
- (2015) Talha Khan Burki LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Substantial contribution of extrinsic risk factors to cancer development
- (2015) Song Wu et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- (2015) O. A. Zill et al. Cancer Discovery
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Transforming Growth Factor- as a Therapeutic Target in Hepatocellular Carcinoma
- (2014) G. Giannelli et al. CANCER RESEARCH
- CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
- (2014) A. M. Heilmann et al. CANCER RESEARCH
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
- (2014) B. Alagesan et al. CLINICAL CANCER RESEARCH
- Maintenance therapy in ovarian cancer
- (2014) Saira Khalique et al. CURRENT OPINION IN ONCOLOGY
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice
- (2014) Wei Wang et al. GASTROENTEROLOGY
- Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor
- (2014) Lingyun Qin et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
- (2014) Andrea Viale et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic predisposition to pancreatic cancer
- (2014) Paola Ghiorzo WORLD JOURNAL OF GASTROENTEROLOGY
- Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer
- (2013) Minoru Oshima et al. ANNALS OF SURGERY
- Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer
- (2013) Stefan Eser et al. CANCER CELL
- Genetic Alterations Associated With Progression From Pancreatic Intraepithelial Neoplasia to Invasive Pancreatic Tumor
- (2013) Stephen J. Murphy et al. GASTROENTEROLOGY
- Mutant KRAS is a druggable target for pancreatic cancer
- (2013) E. Zorde Khvalevsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
- (2012) Carolina Navas et al. CANCER CELL
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway
- (2012) Wei Jiang et al. CELL RESEARCH
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
- (2010) Asfar S. Azmi et al. EUROPEAN JOURNAL OF CANCER
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
- (2009) A. Blackford et al. CLINICAL CANCER RESEARCH
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started